In last trading session, Edwards Lifesciences Corp (NYSE:EW) saw 45.93 million shares changing hands with its beta currently measuring 1.12. Company’s recent per share price level of $59.70 trading at -$27.25 or -31.34% at ring of the bell on the day assigns it a market valuation of $35.98B. That closing price of EW’s stock is at a discount of -61.01% from its 52-week high price of $96.12 and is indicating a discount of -1.46% from its 52-week low price of $60.57. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.37 million shares which gives us an average trading volume of 2.86 million if we extend that period to 3-months.

For Edwards Lifesciences Corp (EW), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.30. Splitting up the data highlights that, out of 17 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 14 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Edwards Lifesciences Corp (NYSE:EW) trade information

Upright in the red during last session for losing -31.34%, in the last five days EW remained trading in the red while hitting it’s week-highest on Monday, 07/22/24 when the stock touched $59.70 price level, adding 32.54% to its value on the day. Edwards Lifesciences Corp’s shares saw a change of -21.70% in year-to-date performance and have moved -30.43% in past 5-day. Edwards Lifesciences Corp (NYSE:EW) showed a performance of -34.45% in past 30-days. Number of shares sold short was 7.7 million shares which calculate 2.28 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 100 to the stock, which implies a rise of 40.3% to its current value. Analysts have been projecting 70 as a low price target for the stock while placing it at a high target of 140. It follows that stock’s current price would drop -17.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -17.25% for stock’s current value.

Edwards Lifesciences Corp (EW) estimates and forecasts

Statistics highlight that Edwards Lifesciences Corp is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -17.70% of value to its shares in past 6 months, showing an annual growth rate of 10.36% while that of industry is 12.10. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.35% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 9.04% while estimates for its earnings growth in next 5 years are of 10.72%.

EW Dividends

Edwards Lifesciences Corp is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Edwards Lifesciences Corp (NYSE:EW)’s Major holders

Insiders are in possession of 0.89% of company’s total shares while institution are holding 84.58 percent of that, with stock having share float percentage of 85.34%. Investors also watch the number of corporate investors in a company very closely, which is 84.58% institutions for Edwards Lifesciences Corp that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at EW for having 52.96 million shares of worth $5.06 billion. And as of 2024-03-31, it was holding 8.7516 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 52.42 million shares on 2024-03-31. The number of shares represents firm’s hold over 8.6615 of outstanding shares, having a total worth of $5.01 billion.